A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Stony Brook University, Stony Brook

University of Rochester Medical Center, Rochester

RCCA MD LLC (The Center for Cancer and Blood Disorders), Bethesda

UVA Health System Division of Hematology & Oncology, Charlottesville

Southeastern Medical Oncology Center, Goldsboro

Duke University Medical Center, Durham

Georgia Cancer Center at Augusta University, Augusta

georgia cancer Center, Augusta

University Hospitals Cleveland Medical Center, Cleveland

Oncology Hematology Care, Cincinnati

Michigan Center of Medical Research, Farmington Hills

Michigan State University, Breslin Cancer Center, Lansing

Medical College of Wisconsin, Milwaukee

Universityof Wisconsin Clinical Science Center, Madison

university of minnesota medical Center, Fairview, Minneapolis

Mercy Medical Research Institute, Springfield

Pontchartrain cancer Center, Covington

Cancer Centers of Southwest Oklahoma, Lawton

Oklahoma Cancer Specialists and Research Institute, Tulsa

UT Southwestern Medical Center, Dallas

New Mexico Cancer care Alliance, Albuquerque

City of Hope, Duarte

Scripps Cancer Center-Mercy, San Diego

Providence Portland Medical center, Portland

Swedish Cancer Institute, Seattle